Скачать книгу - Pharma-Ecology

Полный вариант заголовка: «Manuel complet, theorique et pratique, de pharmacie populaire : Tome 1 : simplifiee et mise a la portee de toutes les classes de la societe / par M. Julia de Fontenelle».

We are facing a future of unbounded complexity. Whether that complexity is harnessed to build a world that is safe, pleasant, humane and profitable, or whether it causes us to careen off a cliff into an abyss of mind-numbing junk is an open question. The challenges and opportunities–technical, business, and human–that this technological sea change will bring are without precedent. Entire industries will be born and others will be laid to ruin as our society navigates this journey. There are already many more computing devices in the world than there are people. In a few more years, their number will climb into the trillions. We put microprocessors into nearly every significant thing that we manufacture, and the cost of routine computing and storage is rapidly becoming negligible. We have literally permeated our world with computation. But more significant than mere numbers is the fact we are quickly figuring out how to make those processors communicate with each other, and with us. We are about to be faced, not with a trillion isolated devices, but with a trillion-node network: a network whose scale and complexity will dwarf that of today’s Internet. And, unlike the Internet, this will be a network not of computation that we use, but of computation that we live in. Written by the leaders of one of America’s leading pervasive computing design firms, this book gives a no-holds-barred insiders’ account of both the promise and the risks of the age of Trillions. It is also a cautionary tale of the head-in-the-sand attitude with which many of today’s thought-leaders are at present approaching these issues. Trillions is a field guide to the future–designed to help businesses and their customers prepare to prosper, in the information.

An in-depth look at big pharma's flagship company The Merck Druggernaut takes readers inside Merck, the world's second most profitable drug company and maker of the world's bestselling drug, Prilosec. Consistently named one of Fortune magazine's Most Admired Companies, Merck struggles to maintain its reputation for being the most ethical of the big drug makers, refusing to slash research and development budgets in the face of declining profits, falling stock market prices, and questionable accounting. Author Fran Hawthorne, one of the leading journalists covering healthcare, has written an excellent examination of a business paragon with much-needed insight on the cutthroat world of pharmaceuticals. It's a story that will interest the business world as well as consumer and healthcare advocates by detailing the vital issues in medicine and healthcare today. More than just a compelling story of success in a difficult industry, more than simply the biography of one of big business's most recognizable names, The Merck Druggernaut takes a thoughtful look at some of the major issues of our time and the way those issues intertwine with the world of business. Fran Hawthorne (New York, NY) is the Assistant Managing Editor at Crain's New York Business. She has been covering business for more than twenty years for such publications as Fortune, BusinessWeek, and Institutional Investor, with a prevailing interest in healthcare and pharmaceuticals. At Crain's, she spearheads the publication of two to three special healthcare issues per year.

This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes–both economic and scientific–of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.

Buildings consume 40% of our planet’s materials and 30% of its energy. Their construction uses up to three million tonnes of raw materials a year and generates 20% of the soild waste stream. If we want to survive our urban future, there is no option but to build in ways which improve the health of ecosystems. Understanding the concept of ecological sustainability and translating it into practice as sustainable development is a key challenge for today’s built environment professionals. The skill and vision of those who shape our cities and homes is vital to achieving sustainable solutions to the many environmental, economic and social problems we face on a local, national and global scale. Peter Graham offers here a holistic view of ecologically sustainable building by drawing on established areas of knowledge, demonstrating their relevance to the environmentally-conscious building professional and putting the process, product and impact of building into context. Case studies illustrate how sustainable principles have been applied successfully and discussion topics are offered to stimulate thought. Building Ecology will help planners, surveyors, designers and builders to incorporate sustainability into their everyday practice by: · showing which styles of building are ecologically sustainable · providing fundamental knowledge for making decisions using the principles of ecologically sustainable building · explaining a complex subject in a clear, balanced way. Building Ecology sets out the current scientific view of how nature works and how buildings link with and affect nature. It provides fundamental knowledge for building in harmony with nature and keeping Earth’s life-supporting ecosystems healthy.